Savant Capital LLC Sells 7,558 Shares of STERIS plc $STE

Savant Capital LLC decreased its position in shares of STERIS plc (NYSE:STE) by 74.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,657 shares of the medical equipment provider’s stock after selling 7,558 shares during the quarter. Savant Capital LLC’s holdings in STERIS were worth $674,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in STE. Jones Financial Companies Lllp grew its stake in STERIS by 46.1% in the first quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after purchasing an additional 349 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in STERIS by 32.3% in the first quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock valued at $55,015,000 after purchasing an additional 59,264 shares during the last quarter. Empowered Funds LLC grew its stake in STERIS by 16.1% in the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock valued at $522,000 after purchasing an additional 319 shares during the last quarter. Woodline Partners LP grew its stake in STERIS by 40.0% in the first quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after purchasing an additional 2,372 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in STERIS by 38.9% in the first quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after purchasing an additional 5,803 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

STERIS Trading Up 0.3%

Shares of NYSE:STE opened at $210.29 on Thursday. STERIS plc has a 52-week low of $195.14 and a 52-week high of $269.44. The stock has a market cap of $20.52 billion, a price-to-earnings ratio of 26.52 and a beta of 0.93. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. The business has a 50-day moving average price of $217.68 and a 200-day moving average price of $239.61.

STERIS (NYSE:STE) last announced its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same quarter in the previous year, the business earned $2.74 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities analysts predict that STERIS plc will post 11.18 EPS for the current year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Analyst Ratings Changes

STE has been the subject of several recent analyst reports. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. KeyCorp lowered their price target on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Weiss Ratings downgraded STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Finally, Piper Sandler reissued an “overweight” rating and issued a $270.00 price target on shares of STERIS in a report on Thursday, May 21st. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, STERIS has an average rating of “Moderate Buy” and an average target price of $278.00.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.